Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine

Journal of Medicinal Chemistry

Volumn 46, Issue 1, 2003, Pages 169-182

  Hay, Michael P ^a   Gamage, Swarna A ^a   Kovacs, Mary S ^b   Pruijn, Frederik B ^a   Anderson, Robert F ^a   Patterson, Adam V ^a   Wilson, William R ^a   Brown, J Martin ^b   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 BENZOTRIAZINE 1,4 DIOXIDE; TIRAPAZAMINE;

ANIMAL CELL; ARTICLE; CELL KILLING; CHEMICAL STRUCTURE; CLONOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; ELECTRON; ELECTRONICS; HYDROPHOBICITY; HYPOXIA; IN VITRO STUDY; MOUSE; NONHUMAN; PREDICTION; REDUCTION; SOLUBILITY; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL HYPOXIA; CYCLIC N-OXIDES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MICE; OXIDATION-REDUCTION; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0037413529     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020367+     Document Type: Article

References (47)

1. Kennedy, A. S.; Raleigh, J. A.; Perez, G. M.; Calkins, D. P.; Thrall, D. E.; Novotny, D. B.; Varia, M. A. Proliferation and hypoxia in human squamous cell carcinoma of the cervix - First report of combined immunohistochemical assays. Int. J. Radiat. Oncol. Biol. Phys. 1997, 37, 897-905.
2. Movsas, B.; Chapman, J. D.; Horwitz, E. M.; Pinover, W. H.; Greenberg, R. E.; Hanlon, A. L.; Iyer, R.; Hanks, G. E. Hypoxic regions exist in human prostate carcinoma. Urology 1999, 53, 11-18.
3. Brizel, D. M.; Dodge, R. K.; Clough, R. W.; Dewhirst, M. W. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother., Oncol. 1999, 53, 113-117.
4. Brown, J. M.; Siim, B. G. Hypoxia-specific cytotoxins in cancer therapy, Semin. Radiat. Oncol. 1996, 6, 22-36.
5. Denny, W. A.; Wilson, W. R.; Hay, M. P. Recent developments in the design of bioreductive drugs. Br. J. Cancer 1996, 74 (Suppl. XXVII), 32-38.
6. Stratford, I. J.; Workman, P. Bioreductive drugs into the next millennium. Anti-Cancer Drug Des. 1998, 13, 519-528.
7. Brown, J. M. SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumors. Br. J. Cancer 1993, 67, 1163-1170.
8. Kelson, A. B.; McNamara, J. P.; Pandey, A.; Ryan, K. J.; Dorie, M. J.; McAfee, P. A.; Menke, D. R.; Brown, J. M.; Tracy, M. 1,2,4-Benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxins with antitumor activity. Anti-Cancer Drug Des. 1998, 13, 575-592.
9. Lee, W. W.; Brown, J. M.; Grange, E. W.; Martinez, A. P.; Tracy, M.; Pollart, D. J. 1,2,4-Benzotriazine oxides as radiosensitizers and selective cytotoxic agents. PCT Patent WO9104028, April 1991.
10. Denny, W. A.; Wilson, W. R. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Exp. Opin. Invest. Drugs 2000, 9, 2889-2901.
11. Lloyd, R. V.; Duling, D. R.; Rumyantskeva, G. V.; Mason, R. P.; Brisdon, P. K. Microsomal reduction of 3-amino-1,2,4-benzotriazine-1,4-dioxide to a free radical. Mol. Pharmacol. 1991, 40, 440-445.
12. Walton, M. I.; Wolf, C. R.; Workman, P. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem. Pharmacol. 1992, 44, 251-259.
13. Patterson, A. V.; Barham, H. M.; Chinje, E. C.; Adams, G. E.; Harris, A. L.; Stratford, I. J. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br. J. Cancer 1995, 72, 1144-1150.
14. Patterson, A. V.; Saunders, M. P.; Chinje, E. C.; Patterson, L. H.; Stratford, I. J. Enzymology of tirapazamine metabolism: A review. Anti. Cancer Drug Des. 1998, 13, 541-573.
15. Fitzsimmons, S. A.; Lewis, A. D.; Riley, R. J.; Workman, P. Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR4233) to a DNA damaging species - A direct role for NADPH-cytochrome P450 oxidoreductases. Carcinogenesis 1994, 15, 1503-1510.
16. Baker, M. A.; Zeman, E. M.; Hirst, V. K.; Brown, J. M. Metabolism of SR 4233 by Chinese hamster ovary cells: Basis of selective hypoxic cytotoxicity. Cancer Res. 1988, 48, 5947-5952.
17. Priyadarsini, K. I.; Tracy, M.; Wardman, P. The one electron reduction potential of 3-amino-1,2,4-benzotriazine 1,4-dioxide (Tirapazamine): A hypoxia-selective bioreductive drug. Free Radical Res. 1996, 25, 393-399.
18. Daniels, J. S.; Gates, K. S. DNA cleavage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR4233). Evidence for involvement of hydroxyl radical. J. Am. Chem. Soc. 1996, 118, 3380-3385.
19. Wang, J.; Biedermann, K. A.; Brown, J. M. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res. 1992, 52, 4473-4477.
20. von Pawel, J.; von Roemeling, R.; Gatzemeier, U.; Boyer, M.; Elisson, L. O.; Clark, P.; Talbot, D.; Rey, A.; Butler, T. W.; Hirsh, V.; Olver, I.; Bergman, B.; Ayoub, J.; Richardson, G.; Dunlop, D.; Arcenas, A.; Vescio, R.; Viallet, J.; Treat, J. Tirapazamine plus cisplatin versus cisplatin in advanced non small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non small-cell lung tumors. J. Clin. Oncol. 2000, 18, 1351-1359.
21. Lee, D. J.; Trotti, A.; Spencer, S.; Rostock, R.; Fisher, C.; von Roemeling, R.; Harvey, E.; Groves, E. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: A Phase II study. Int. J. Radiat. Oncol., Biol., Phys. 1998, 42, 811-815.
22. Del Rowe, J.; Scott, C.; Werner-Wasik, M.; Bahary, J. P.; Curran, W. J.; Urtasun, R. C.; Fisher, B. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J. Clin. Oncol. 2000, 18, 1254-1259.
23. Brown, J. M.; Koong, A. Therapeutic advantage of hypoxic cells in tumors: A theoretical study. J. Natl Cancer Inst. 1991, 83, 178-185.
24. Zeman, E. M.; Baker, M. A.; Lemmon, M. J.; Pearson, C. I.; Adams, J. A.; Brown, J. M.; Lee, W. W.; Tracy, M. Structure-activity relationships for benzotriazine di-N-oxides. Int. J. Radiat. Oncology Biol. Phys. 1989, 16, 977-981.
25. Arndt, F. Ring-closing between nitro and amino groups forming triazines. Ber. 1913, 46, 3522-3529.
26. Mason, J. C.; Tennant, G. Heterocyclic N-oxides. Part VI. Synthesis and nuclear magnetic resonance spectra of 3-aminobenzo-1,2,4-triazines and their mono- and di-N-oxides. J. Chem. Soc. (B) 1970, 911-916.
27. Pazdera, P.; Potacek, M. 4-Substituted 2-nitrophenylguanidines I. Synthesis and cyclization of 4-substituted 2-nitrophenylguanidines. Chem. Papers 1988, 42, 527-537.
28. Newman, M. S.; Karnes, H. A. The conversion of phenols to thiophenols via dialkylthiocarbamates. J. Org. Chem. 1966, 31, 3980-3984.
29. Seko, S.; Miyake, K.; Kawamura, N. A convenient copper-catalyzed direct amination of nitroarenes with O-alkylhydroxylamines. J. Chem. Soc., Perkin Trans. 1 1999, 1437-1444.
30. Makosza, M.; Bialecki, M. Nitroarylamines via the vicarious nucleophilic substitution of hydrogen: Amination, alkylamination, and arylamination of nitroarenes with sulfenamides. J. Org. Chem. 1998, 63, 4878-4888.
31. Siim, B. G.; Hicks, K. O.; Pullen, S. M.; van Zijl, P. L.; Denny, W. A.; Wilson, W. R. Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs - Cytotoxicity, DNA binding, cellular uptake, and metabolism. Biochem. Pharmacol. 2000, 60, 969-978.
32. Patel, K. B.; Willson, R. L. Semiquinone free radicals and oxygen. Pulse radiolysis study of one electron equilibria. J. Chem. Soc., Faraday Trans. 1973, 69, 814-819.
33. Wilson, W. R.; Thompson, L. H.; Anderson, R. F., Denny, W. A. Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine analogues. J. Med. Chem. 1989, 32, 31-38.
34. Siim, B. G.; Wilson, W. R. Efficient redox cycling of nitroquinoline bioreductive drugs due to aerobic nitroreduction in chinese hamster cells. Biochem. Pharmacol. 1995, 50, 75-82.
35. Rischin, D.; Peters, L.; Hicks, R.; Hughes, P.; Fisher, R.; Hart, R.; Sexton, M.; D'Costa, I.; von Roemeling, R. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J. Clin. Oncol. 2001, 19, 535-542.
36. Evans, J. W.; Yudoh, K.; Delahoussaye, Y. M.; Brown, J. M. Tirapazamine is metabolized to its DNA damaging radical by intranuclear enzymes. Cancer Res. 1998, 58, 2098-2101.
37. Wouters, B. G.; Delahoussaye, Y. M.; Evans, J. W.; Birrel, G. W.; Dorie, M. J.; Wang, J.; MacDemed, D.; Chiu, R. K.; Brown, J. M. Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine. Cancer Res. 2001, 61, 145-152.
38. Delahoussaye, Y. M.; Hay, M. P.; Pruijn, F. B.; Denny, W. A.; Brown, J. M. Unpublished results.
39. Shigyo, H.; Sato, S.; Shibuya, K.; Takahashi, Y.; Yamaguchi, T.; Sonoki, H.; Ohta, T. Synthesis and antiarrhythmic activity of disubstituted phenylpyridine derivative. Chem. Pharm. Bull. 1993, 41, 1573-1582.
40. Suzuki, H.; Kawakami, T. A convenient synthesis of 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR 4233) and related compounds via nucleophilic aromatic substitution between nitroarenes and guanidine base. Synthesis 1977, 855-857.
41. Friebe, W. G.; Scheuer, W.; Tibes, U. Benzotriazines, pharmaceutical compositions, and methods of using same. US Patent 5856325, Jan 1999.
42. Robbins, R. F.; Schofield, K. Polyazabicyclic compounds. Part II. Further derivatives of benzo-1,2,4-triazine. J. Chem. Soc. 1957, 3186-3194.
43. Lee, W. W.; Brown, J. M.; Grange, E. W.; Martinez, A. P.; Tracy, M.; Pollart, D. J. 1,2,4-Benzotriazine oxides as radiosensitizers and selective cytotoxic agents. US Patent 5624925, April 1997.
44. Wardman, P. Reduction potentials of one-electron couples involving free radicals in aqueous solution. J. Phys. Chem. Ref. Data 1989, 18, 1637-1755.
45. Van Leeuwen, J. W.; Van Dijk, C.; Veeger, C. A pulse radiolysis study of the reduction of flavodoxin from Megasphaera elsdenii by viologen radicals. Eur. J. Biochem. 1983, 135, 601-607.
46. Stekhan, E.; Kuwana, T. Spectroelectrochemical study of mediators. I. Bipyridylium salts and their electron-transfer rates to cytochrome C. Ber. Bunsen-Ges. Physik Chem. 1974, 78, 253-259.
47. Anderson, R. F. Electron transfer and equilibria between pyridinyl radicals and FAD. Ber. Bunsen-Ges. Physik Chem. 1976, 80, 969-972.